In this meta-analysis of six randomized trials, prophylactic use of ARBs/ACEIs or BBs did not reduce the risk of trastuzumab-related cardiotoxicity in HER-2 positive breast cancer patients. Here, ERBB2 is linked to breast carcinoma.